# Vishal Patel

> Vishal Patel is the co-founder and CEO of Triveni Bio, a Watertown, Massachusetts biotech betting that genetics, not trial-and-error, should decide which antibodies reach patients with immune and inflammatory diseases. He stitched the company together from a two-startup merger, raised more than $200 million across Series A and B rounds, and pointed its lead programs at the skin enzymes behind atopic dermatitis. A Harvard PhD and MIT MBA who once helped draft healthcare legislation on Capitol Hill and still serves as a US Navy reservist, Patel runs a lab while keeping a foot in venture as an Atlas advisor.

- **Role:** Co-Founder and Chief Executive Officer at Triveni Bio
- **Organizations:** Triveni Bio, Atlas Venture, Flagship Pioneering, Novartis, Merck KGaA, U.S. Navy Reserve
- **Nationality:** American
- **Education:** PhD in Biological Chemistry and Molecular Pharmacology (National Science Foundation Fellow), Harvard University, MBA, Massachusetts Institute of Technology (MIT), BS in Bioengineering, University of Illinois
- **Known for:** Co-founded Triveni Bio and built it from a two-company merger into a funded clinical-stage biotech, Raised more than $200 million across Series A ($92M) and Series B ($115M) financings, Led Triveni to a Fierce Biotech 'Fierce 15' Biotech Company of 2025 designation

## Career timeline

- **—** — Earned BS in Bioengineering at University of Illinois
- **—** — Worked in U.S. government, including U.S. Department of State and U.S. Senate, contributing to drafting the Affordable Care Act
- **—** — PhD at Harvard as a National Science Foundation Fellow; MBA at MIT
- **—** — Held roles of increasing responsibility at Merck KGaA
- **—** — VP of Strategy and Scientific Engagement at Novartis, overseeing R&D strategy and portfolio management
- **—** — Head of Portfolio Strategy and Alliances at Flagship Pioneering
- **2023** — Co-founded and became CEO of Triveni Bio, formed via merger of Amagma Therapeutics and Modify Therapeutics; closed $92M Series A
- **2024** — Raised $115M Series B led by Goldman Sachs Alternatives
- **2025** — Triveni Bio named a Fierce 15 Biotech Company of 2025

## Achievements

- Co-founded Triveni Bio and built it from a two-company merger into a funded clinical-stage biotech
- Raised more than $200 million across Series A ($92M) and Series B ($115M) financings
- Led Triveni to a Fierce Biotech 'Fierce 15' Biotech Company of 2025 designation
- Advanced lead program TRIV-509 toward IND submission for atopic dermatitis
- National Science Foundation Fellow during PhD at Harvard

## Latest updates

- **2024-10** — Triveni Bio closed a $115 million Series B led by Goldman Sachs Alternatives to advance its bispecific program TRIV-573 and expand its precision-dermatology data platform.
- **2025-01** — Triveni planned an IND submission for lead antibody TRIV-509 in atopic dermatitis.
- **2025-01** — Triveni Bio named a Fierce 15 Biotech Company of 2025.

## Links

- Website: https://triveni.bio
- LinkedIn: http://www.linkedin.com/in/vishal-patel-98284354

---

Profile page: https://yespress.io/vishal-patel
Published by YesPress — https://yespress.io
Last updated: 2026-06-04